Andrew Tutt

Andrew Tutt

Honorary consultant clinical oncologist


Andrew Tutt is a consultant clinical oncologist in the breast unit and Professor of oncology at King’s College London.

He trained in clinical oncology at the Royal Marsden Hospital London and in breast cancer research at The Institute of Cancer Research, where he gained his PhD in cancer biology.

Professor Tutt focuses his practice exclusively on breast cancer, both in clinical breast oncology and in radiotherapy. He is a member of the St Gallen Early Breast Cancer International Guidelines Consensus Panel. He has a particular research interest in “triple negative” and BRCA1 and BRCA2 associated breast cancers where he leads a number of international clinical trials and is the director of a laboratory research programme focusing on these areas. Professor Tutt is a member of a UK team testing new techniques in breast radiotherapy and has written review articles on this topic in international journals.

He has published and presented a large number of breast cancer research papers and is an invited speaker and session chair at major European and North American Cancer Medicine conferences.

Education and training

  • PhD (cancer biology), The Institute of Cancer Research, University of London, June 2002
  • FRCR Oncology (Rohan Williams Gold Medal) April 1997
  • MRCP (UK) February 1993
  • MB ChB (Bristol) 
  • Distinction in clinical pathology, epidemiology, public health medicine, June 1990

Specialist oncology training:

  • Specialist registrar in clinical oncology (Year 5) clinical oncology rotation, Guy’s, King’s and St Thomas’ Cancer Centre, September 2001 - March 2003
  • Clinical research fellow (honorary senior registrar),Royal Marsden Hospital NHS Trust, breast unit, October 1997 - August 2001
  • Specialist registrar in clinical oncology (Years 1-4) clinical oncology rotation, Royal Marsden Hospital NHS Trust, January 1994 - September 1997

Research training:

  • MRC clinical research training fellow
  • BRCA2 gene function team (Ashworth Laboratory)
  • Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London

PhD Project: ‘Role of the BRCA2 protein in the maintenance of genome stability’. Supervisors: Professor Alan Ashworth and Dr Gillian Ross

Research interests

  • Director of Breakthrough Breast Cancer Research Unit at King’s College London.
  • Therapeutic and biomarker development in BRCA1 / BRCA2 and triple negative breast cancers


  • Jean H. Lubrano Distinguished Visiting Scholar, Harvard Medical School, June 2010
  • Visiting Professor, British Columbia Cancer Agency, Vancouver, October 2009
  • AstraZeneca Scholars Award, 24th San Antonio International Breast Cancer Symposium, December 2001

Last updated: June 2021

Is this page useful?